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Abstract Objective: The aim of the present study was to
evaluate the pharmacokinetic profile of lamotrigine (LTG)
in epileptic patients submitted to video-electroencepha-
lography (VEEG) monitoring and, in addition, to inves-
tigate the influence of concomitant antiepileptic drugs
(AEDs) on the kinetics of LTG. Methods: The analysis
assumed a one-compartment open model with first-order
absorption and elimination. The kinetic estimates obtained
in this population were validated by using the Prediction-
Error approach. The influence of medication was also
assessed by the calculation of the LTG concentration-to-
dose ratio. Patients (n=135) were divided into four groups
according to the co-medication: Group 1, patients taking
LTG with enzyme-inducer agents; Group 2, patients
receiving LTG with valproic acid; Group 3, patients
receiving both inducers and inhibitors of LTG metabolism;
Group 4, patients under AEDs not known to alter LTG
metabolism. Results: The obtained estimates for clear-
ance (CL) (L/h/kg) [0.075±0.029 (Group 1), 0.014±0.005
(Group 2), 0.025±0.008 (Group 3) and 0.044±0.011
(Group 4)] appear to be the most appropriate set to be
implemented in clinical practice as prior information, as
demonstrated by the accuracy and precision of the
measurements. In addition, the influence of co-medication
on the LTG profile was further confirmed by the basal
LTG concentration-to-dose ratio. Conclusion: The results
of the present investigation may contribute to achieving
the goal of optimizing patients’ clinical outcomes by
managing their medication regimen through measured
drug concentrations. Patients submitted to VEEG mon-
itoring may benefit from this study, as the results may be
used to provide better drug management in this medical
setting.
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Introduction
The selection of an antiepileptic drug (AED) is guided by
the aim of achieving maximum seizure control with
minimum side effects. In the search for better approaches
to refractory epilepsy, a new generation of AEDs has
emerged. Lamotrigine (LTG) is a widely used AED
currently available in more than 90 countries. It was
introduced as adjunct treatment of partial seizures in
Europe in 1991 and in the United States in 1994. It has
recently been suggested that LTG may be useful as initial
monotherapy in patients with newly diagnosed epilepsy
[1–3]. At the present time it has the approval of the U.S.
Federal Drug Administration as a monotherapy, following
conversion in patients receiving AEDs with enzyme-
inducing properties. Furthermore, there is an increasing
interest in its properties for treating bipolar disorders [4].
Lamotrigine is metabolized mainly in the liver by
glucuronidation and excreted renally as a glucuronide
conjugate [5, 6]. The metabolism of LTG is catalysed by
UDPGT1A4, an isoenzyme of the uridine 5′-diphosphate-
glucuronosyltransferase (UDPGT) family of enzymes [7].
The coadministration of hepatic enzyme-inducing (IND)
agents, such as phenytoin (PHT), carbamazepine (CBZ),
phenobarbitone (PB) or primidone (PRM), significantly
increases the systemic clearance of LTG [8], while valproic
acid (VPA), a known inhibitor of glucuronidation,
significantly reduces the elimination of LTG [9, 10].
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Although polytherapy regimens heighten the risk of side
effects and drug interactions, consequently reducing patient
compliance and raising therapy costs, the epileptic popula-
tion often presents complex concurrent therapies. In addi-
tion, several characteristics of LTG would suggest that there
is a clinical need to individualize patient therapy through the
use of therapeutic drug monitoring (TDM) [11–13]. In
addition, patients submitted to video-electroencephalogra-
phy (VEEG) monitoring for diagnostic purposes often agree
to AED discontinuation in order to precipitate seizures. A
knowledge of the kinetic behaviour of LTG in this
subpopulation may contribute to the better management of
these patients in that this kinetic information could be used
to predict LTG concentrations in this clinical setting.
The aim of the present study was therefore (1) to
estimate LTG pharmacokinetic parameters, (2) to validate
this estimation by using prediction performance analysis
and (3) to further investigate the influence of concomitant
AEDs on LTG kinetics by assessing the concentration-to-
dose (C/D) ratio.
Materials and methods
Patients
The study was conducted in the VEEG Monitoring Unit of
the Neurology Department of Coimbra University Hospital
(Portugal). Patients receiving LTG were submitted to
VEEG monitoring during a period of 3–11 days for seizure
characterization or presurgical evaluation. Routine haema-
tology and blood chemistry assessments were made. The
local Ethics Committee of Coimbra University Hospital
approved this study, and written informed consent was
obtained from all patients.
During the VEEG session, patients agreed to a drug
discontinuation protocol in order to precipitate seizures –
the methodology adopted in this setting. In the case of
polytherapy, the protocol establishes that the first drug to
be withdrawn is the concomitant CBZ or VPA. If both
drugs are present simultaneously, the withdrawal should
start with CBZ.
A total of 652 serum concentrations (peaks and troughs)
of 135 Caucasian patients were evaluated. Data were
collected from October 1998 to June 2005. Demographic
data collected included date of birth, gender, weight,
height, medical history and dosage regimens (dose and
frequency of dosage), with all details of concomitant
medication. The LTG baseline dosage regimen was
recorded when the patient arrived at the hospital. The
collected data were further matched with individual clinical
reports.
Lamotrigine was administered orally, ranging from 25 to
500 mg one to four times daily (Table 1). Patients were
included in the study if they their LTG-dose and co-
medication had remained unchanged during a period of at
least 20 days (fivefold the maximum half-life, which may
reach approximately 89 h when associated to VPA).
Blood sampling and assay
Blood samples were collected just prior to the following
dose to obtain minimal (or trough) concentrations each
morning during the VEEG session. As trough concentra-
tions are insufficient to achieve a complete characterization
of the pharmacokinetic profile, two additional sampling
time points were established near the tmax of lamotrigine.
Blood samples were characterized by high-performance
liquid chromatography (HPLC), as described elsewhere
[14]. Calibration between 0.1 and 15.0 mg/L of LTG
concentration provided good accuracy (a mean of 0.013 for
the inter-assay), precision (a mean of 6.97% for the inter-
assay) and recovery (85%) results. The stability of the
samples in this biological fluid at 4° and −25°C has also
been reported previously [14]. The serum concentrations of
the remaining AEDs (CBZ, VPA, FB, and PHT) were
analysed by a fluorescence polarization immunoassay
(FPIA) method (Abbott Diagnostics Division, Maiden-
head, UK) according to the usual analytical procedures.
This approach allowed us to ensure that the patients had
taken AEDs regularly.
Pharmacokinetic analysis
The pharmacokinetic (PK) study of plasma LTG concen-
trations was performed by compartmental analysis, using
the non-linear regression computer program WINNONLIN®
ver. 1.2 (Scientific Consulting, Gaithersburg, Md). The
analysis assumed a one-compartment open model with
first-order absorption and first-order elimination. This
study included 93 patients for the estimation of absorption
rate constant (ka), volume of distribution (Vd) and elim-
ination rate constant (ke). In the individual estimation, the
curve fitting used 4–11 concentrations (peaks and troughs).
The general features of patients included in pharmacoki-
netic study are shown in the Index sample of Table 1. Four
treatment groups could be established taking into account
the existing patient co-medication: Group 1, LTG and
inducer agents; Group 2, LTG and VPA; Group 3, LTG
with both inducers and VPA; Group 4, LTG with neither
inducer nor inhibitor agents able to alter LTG metabolism,
based on present knowledge. In Group 4 only one patient
had LTGmonotherapy; we were also able to find vigabatrin
(VGB; n=1), clobazam (CLB; n=1), topiramate (TPM;
n=3) or gabapentin (GBP; n=1). Group 1 patients could be
further divided into one-inducer (LTG+CBZ; n=33) and
two-inducer (LTG+CBZ+PHT/FB; n=8) subgroups. Three
patients were excluded from Group 1 due to a different
combination of inducers (LTG+PB/PHT, in a total of 15
samples).
To validate the estimates obtained in the pharmacoki-
netic study we investigated their predictive capacity in 42
new patients (Validation sample), using one to three
concentrations per patient (Table 1). This approach
assessed the ability to predict LTG serum concentrations
in advance using the PKS programme (PKS® System,
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Abbott Diagnostics). The absolute and relative predictive
performances were evaluated applying the Prediction-Error
analysis, as suggested by Sheiner & Beal [15]. This
evaluation involved the calculation of mean prediction
error (ME), as a measure of accuracy; mean squared
prediction error (MSE), representing precision; the root
mean squared prediction error (RMSE), as a measure of
both accuracy and precision. In order to perform this study,
two sets of the obtained parameters were assembled: P1,
which used those parameters obtained with ‘All data’
results (Table 2) to estimate a priori LTG concentrations;
P2, which used the PK parameters obtained in the four
treatment groups described above (Table 2). This latter
approach evaluates the prediction performance of LTG
concentrations using the results obtained in the target
population and also investigates the influence of knowl-
edge of co-medication on this prediction. Furthermore, we
compared the predictive performance of four different sets
of LTG parameters selected from previous published
studies (Table 3). The aim of this approach was to assess
their ability to predict LTG concentrations and to compare
this capacity to that demonstrated by our PK parameter set
which demonstrated the best prediction results.
The trough steady-state serum concentrations (mg/L)
normalized by daily dose (mg/kg/day) – the C/D ratio –may
be used to evaluate the influence of co-medication on LTG
treatment [16–19]. Consequently, we decided to pool data
(Index and Validation sample) in order to determine the LTG
C/D ratio in our patients. This investigation used the first
basal LTG concentration level of each patient divided by the
respective LTG dose (mg/kg/day) to calculate the basal LTG
C/D ratio. We considered basal levels to be each trough
concentration measured before the start of drug withdrawal.
Using the same criteria for establishing categories described
Table 2 Summary of LTG pharmacokinetic parametersa obtained in the study
Parametersb Treatment groupc All data
Group 1 Group 2 Group 3 Group 4
Number of patients 41 28 14 7 90
Number of concentrations 260 183 79 38 562
ka (h
−1) 1.28±1.09 1.67±1.44 1.55±1.06 1.82±1.64 1.49±1.24
Vd/F (L/kg) 1.02±0.29 0.86±0.27 0.90±0.31 1.08±0.34 0.96±0.30
t½ (h) 10.5±4.5 42.4±11.2 26.7±10.7 18.2±7.6 23.5±16.2
CL (L/h/kg) 0.075±0.029* 0.014±0.005* 0.025±0.008* 0.044±0.011* 0.046±0.034
*p≤0.001 (statistical differences were found between all groups)
aResults are expressed as the mean ± standard deviation
bka, absorption rate constant; Vd, volume of distribution; ke, elimination rate constant; t½ time required for 50% elimination
cGroup 1, LTG+IND; Group 2, LTG+VPA; Group 3, LTG+VPA+IND; Group 4, LTG+NONE (IND, metabolism inducer; VPA, valproic
acid; VPA+IND, valproic acid and inducer; NONE, AEDs not known to modify drug metabolism
Table 1 Summary of patient characteristics
Populationa
Index Validation
Number of patients 90 42
Number of observations per patient 4–11 1–3
Number of concentrations 560 77
Female/male 47/43 27/15
Age (years)b 31.4±12.2 (12–64) 29.5±10.9 (12–53)
Weight (kg)b 67.4±13.7 (41–105) 67.2±17.6 (36–108)
Height (cm)b 164.7±9.7 (148–192) 163.2±9.3 (130–183)
Time intervalb, c (h) 13.2±2.8 (6.3–24.6) 12.3±3.4 (4.0–24.0)
Co-medicationd (no of patients)
Group 1 41 14
Group 2 28 12
Group 3 14 8
Group 4 7 8
aIndex, Patients included in the pharmacokinetic study; validation, patients included in the prediction performance study
bResults expressed as the mean ± standard deviation (range in parenthesis)
cBetween last intake and blood sampling considering basal levels; only 5% presented the 1 id-scheme (1+0+0) and 1% presented the
4 id-scheme (1+1+1+1)
dGroup 1, LTG+IND; Group 2, LTG+VPA; Group 3, LTG+VPA+IND; Group 4, LTG+NONE (IND, metabolism inducer; VPA, valproic
acid; VPA+IND, valproic acid and inducer; NONE, AEDs not known to modify drug metabolism)
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before, four treatment groups were established in accor-
dance with LTG co-medication.
The SPSS® (release 11.5 for Windows, 2002; SPSS,
Chicago, Ill.) was used to operate all statistical tests.
Parametric statistical calculations were used because the
data were normally distributed. The significant probability
level chosen was p≤0.05.
Results
A summary of the pharmacokinetic estimates is shown in
Table 2. No statistical difference was found between
groups based on a comparison of the Vd/F and ka estimates.
However, the data did exhibit significant differences in
clearance (CL) estimates between the four groups estab-
lished. In Group 1, patients included in the two-inducer
subgroup (LTG+CBZ+PHT/FB) presented higher clear-
ance estimates (0.098±0.037 L/h/kg; n=8) than the patients
receiving only CBZ (LTG+CBZ) concomitantly with LTG
(0.069±0.024 L/h/kg; n=33).
Predictive performance measures are revealed in Tables 4
and 5. The set of parameters nominated as P2 showed a lower
ME value (0.05 μg/mL) than P1. The P1 set of parameters
showed a slightly negative ME value (−0.98), indicating a
minor underprediction (Table 4). P2 also exhibited a lower
RMSE value than P1 (1.75 vs. 3.00 μg/mL). The comparison
between set P1 and set P2 also revealed significant
differences in the accuracy (p<0.05) and the precision
(p<0.001) measures. The relative evaluation provided a mean
ΔME value of 1.03 [95% confidence interval (CI): 0.40–
1.66) and a meanΔMSE value of 5.97 (95% CI: 2.88–9.05).
Accordingly, set P2 seems to be significantly more accurate
and precise than P1, indicating that knowledge of the co-
medication may contribute to a better prediction of LTG
concentrations. In view of this, P2 was chosen as the
reference methodology for further evaluation with other sets
of PK parameters based on previously published studies
(Table 3). The results of this comparative analysis of both
accuracy (ME) and precision (MSE) are described in Table 5.
The influence of co-medication on the C/D ratio of the
total sample population is presented in Fig. 1. Statistical
differences were found between all groups. No difference
could be discerned by comparing the kind of inducer
included in Group 1 or in Group 3.
Discussion
The results of this pharmacokinetic study involving 90
patients (Index sample) demonstrated a high inter-individ-
ual variability in the estimates of the parameters tested; this
was particularly true for the elimination rate constant (CV:
approx. 70%). Although genetic differences in drug
glucuronidation, due to variable expression of the different
isoenzymes of UDPGT, may contribute to inter-subject
variability in metabolism [20], this high variability between
patients is more likely to be attributed to pharmacokinetic
interactions.
The sampling time schedule used in this clinical setting
allowed us to completely characterize the kinetic profile of
LTG in this sample of patients. The ka and Vd/F estimates
obtained in the 90 patients were similar to the values
obtained in previous studies [5, 21–23].
Carbamazepine, as well as phenytoin, phenobarbital and
primidone, affect the glucuronidation of LTG [24]. In the
present study, the fastest elimination rate constant was
presented by Group 1 (t½=10.5±4.5 h). Jawad et al. also
observed similar results in nine patients taking liver
enzyme-inducing AEDs [16]. The somewhat higher coef-
ficient of variation presented by Group 1 may be attributed
to the higher clearance values obtained in patients included
Table 4 Predictive performance of LTG concentrations
Setsa Prediction-errorb
ME (μg/mL) MSE (μg/mL)2
P1 −0.98 9.01
(−1.63; −0.32)* (5.56; 12.47)
P2 0.05 3.05
(−0.35; 0.45) (1.76; 4.33)
*Significant differences from zero (p≤0.05)
aP1, Parameter set established in accordance with the estimates
ascribed as All data’ (Table 2); P2, parameter set established in
accordance with the estimates achieved in each treatment group
(Table 2)
bValues given are the mean (95% CI is given in parenthesis). ME,
Mean prediction error; MSE, mean squared prediction error; n=77
Table 3 Lamotrigine parameter sets established according to previous published studies
Set number Parametersa n Reference
F ka (h
−1) Vd/F (L/kg) CL/F (L/h/kg)
1 0.98b 6.16 1.28±0.24c 0.049±0.028 22 [8]
2 0.91 1.30 d e 527 [21]
3 0.98b 3.57 1.12±0.07 0.031±0.011 124 [22]
4 0.98b 1.49f 1.10±1.00 0.080±0.080 23 [23]
aF, Bioavailability fraction; ka, absorption rate constant; Vd, volume of distribution; CL, clearance
bBibliographical value was used because no F value was reported in the reference study
cMean ± standard deviation
dAccording to author’s model, Vd=132 L × 0.735 if female
eAccording to author’s model, CL= 40.5+0.428 mL/min × weight × 1.131 if co-medication consists of more than two inducers
fPortuguese ka value was used because no value was available in the reference study
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in the two-inducer subgroup. However, statistical analysis
failed to prove any significant difference between the one-
and two-inducer subgroups, probably due to the small
number of patients involved in the latter. Nonetheless,
vigilance should be taken when this combination is admin-
istered in order to avoid any reduction of LTG concentrations
to negligible values, thereby resulting in the impairment of
its antiepileptic properties. Other non-epilepsy medication
may also reduce LTG levels (e.g. oral contraceptives) [25],
although we found no difference between males and females
with respect to kinetic behaviour.
Group 2 exhibited the longest elimination half-life
(42.4±11.2 h). These results are consistent with those
obtained by Yuen et al. in six volunteers [9]. The use of
low-to-moderate dosages of VPA (1000 mg/day) may
achieve significant increases in LTG plasma concentration
[26]. In fact, the metabolism of drug seems to be inhibited
at very low doses and concentrations of VPA [27]. Thus,
given the high variability demonstrated by our data, it
seems advisable that titration in these patients should be
based on the LTG plasma concentration rather than on the
crude dosage recommendations of manufacturers only.
More recently, some authors have recommended the TDM
of LTG in VPA co-treated patients in order to minimize the
occurrence of side effects in patients with higher LTG
serum levels [28].
The estimates obtained in Group 3 (t½=26.7±10.7 h)
were found to be close to those observed in volunteers in
studies by Cohen et al. [5] and by Jawad et al., in which
they studied 13 patients receiving VPA together with an
inducing AED [8]. These results are probably due to the
capacity of both drugs to counteract the inducing/inhibitory
effect, which may depend on the inducer agent involved.
Phenytoin was reported to have the capacity to compensate
for the inhibitory effect of VPA [16]. However, in Group 3,
CBZ and FB were the main inducer agents found to be
associated to LTG and VPA [CBZ (n=5); FB (n=7); PR
(n=1); PHT (n=1)].
Group 4 was characterized by patients receiving neither
inducers nor inhibitors of LTG metabolism – at least based
on the extent of our present knowledge on the influence of
the new AEDs on LTG kinetics. This group presented a
lower mean half-life estimate (t½=18.2±7.6 h) than Group 3.
Interestingly, in spite of the reduced number of patients
available in this group, a statistical difference between
Group 3 and Group 4 was be found (Table 2). This is a
relevant finding in that it may indicate that the inhibitory
capacity of VPA may not be completely counteracted by the
presence of the inducing agents in Group 3. In order to
evaluate the potential influence of these inducers (FB/PR vs.
CBZ), a t-test was performed. However, no difference could
be found between these drugs in terms of their influence. In
group 4, no significant difference when patients with TPM
(n=3) were compared to those without TPM (n=4), although
the sample size was very small. Nevertheless, clearance
estimates of Group 4 are slightly higher that those obtained
in patients submitted to monotherapy [29].
The validation approach allowed us to consider the ability
of the established sets of PK parameters in predicting LTG
concentrations, so they might be applied in clinical
programmes as prior information which could be used to
optimize dosage of LTG (namely, in the PKS software
application for TDM). The estimation of pharmacokinetic
parameters in the target population, rather than the
Treatment group
Group 4Group 3Group 2Group 1
LT
G
C/
D
ra
tio
4.0
3.5
3.0
2.5
2.0
1.5
1.0
.5
0.0
Fig. 1 Concentration-to-dose (C/D) ratio observed for the four
groups established according to co-medication. Statistical differ-
ences were found between all groups (p≤0.05). Error bars represent
the 95% CI of the means. C/D ratio, LTG concentration (mg/L)
normalized by dose (mg/kg/day). Group 1, LTG+IND; Group 2,
LTG+VPA; Group 3, LTG+VPA+IND; Group 4, LTG+NONE. IND,
inducer; VPA,valproic acid; NONE, AEDs not known to modify
drug metabolism (all data)
Table 5 Relative predictive performance of LTG serum concentrations: comparative analysis of accuracy (ME) and precision (MSE)
Previous published sets vs. P2a
Set number 1 2 3 4
ΔMEb (μg/mL) 1.04 1.79 −0.34 2.22
(0.46; 1.62)* (1.19; 2.39)* (−0.97; 0.28) (1.61; 2.83)*
ΔMSEb (μg/mL)2 −4.38 −7.20 −5.48 −8.88
(−6.48; −2.28)* (−10.77; −3.63)* (−8.75; −2.20)* (−12.83; −4.94)*
*p≤0.05
aP2, Parameter set established in accordance with the estimates achieved in each treatment group (Table 2). Values given are the mean (95%
CI is given in parenthesis)
bME, Mean prediction error; MSE, Mean squared prediction error; n=77
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implementation of parameters established in other popula-
tions, improves individual estimation because it provides a
more accurate and precise dosing regime design based on
prior prediction. The influence of co-medication in this
population was further confirmed by the use of the C/D ratio
(Fig. 1). The present results are consistent with those
reported in previous studies [16, 19].
The knowledge of the kinetic behaviour of the medica-
tions obtained in this medical setting ( a difficult-to-treat
epilepsy condition) may contribute to a better management
of those patients who are submitted to VEEG monitoring
for diagnostic purposes, ultimately helping to optimize the
procedure to be applied in drug withdrawal protocols. This
may be accomplished by using the P2 set of parameters to
predict the LTG concentrations of those patients and, in
addition, to allow its eventual correlation with the dynamic
response.
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